Eculizumab is a drug that is also known as a recombinant monoclonal antibody. This drug binds with complement protein C5 and further prevents cleavage into C5a and C5b which subsequently inhibits the formation of terminal complex C5b-9. This leads to inhibit complement-mediated intravascular haemolysis and thrombotic microangiopathy.